Skip to main content

Advertisement

SpringerLink
Log in

Oral Propranolol Therapy for Infantile Hemangioma: Long-term Follow-up

  • Clinical Brief
  • Published:
Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

β-blocker therapy is currently the treatment of choice for infantile hemangiomas (IH), albeit with limited data on long-term treatment outcomes. Herein, authors treated 67 IH lesions in 47 patients with oral propranolol at 2 mg/kg/d for a median of 9 mo and followed them up for a median of 48 mo. While no maintenance therapy was required for 18 lesions (26.9%), the rest needed maintenance therapy. Both treatment regimens had comparable efficacy (83.3±23.9% and 92.0±13.8%) but chances of IH recurrence was higher in lesions requiring maintenance therapy. Also, patients treated at ≤5 mo of age had a significantly better response and a lower recurrence rate than patients treated at >5 mo of age (95.0±7.9% vs. 87.0±17.5%, p = 0.05). Authors’ experience suggests that longer durations of maintenance therapy offered no added advantage to the overall improvement of IH while treatment initiation at an earlier age showed better improvement and lower recurrence rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25:168–73.

    Article  PubMed  Google Scholar 

  2. Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: Incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170:907–13.

    Article  CAS  Google Scholar 

  3. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143:e20183475.

    Article  PubMed  Google Scholar 

  4. Léauté-Labrèze C, De La Roque ED, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. New Engl J Med. 2008;358:2649–51.

    Article  PubMed  Google Scholar 

  5. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New Engl J Med. 2015;372:735–46.

    Article  PubMed  Google Scholar 

  6. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: A systematic review. Pediatr Dermatol. 2013;30:182–91.

    Article  PubMed  Google Scholar 

  7. Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011;170:493–501.

    Article  CAS  PubMed  Google Scholar 

  8. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: A systematic review. Pediatrics. 2016;138:e20160353.

    Article  PubMed  Google Scholar 

  9. Yang H, Hu D-L, Shu Q, Guo X-D. Efficacy and adverse effects of oral propranolol in infantile hemangioma: A meta-analysis of comparative studies. World J Pediatr. 2019;15:546–58.

    Article  CAS  PubMed  Google Scholar 

  10. Püttgen KB, Hansen LM, Lauren C, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol. 2021;85:345–52.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge Indian Council for Medical Research for funding a part of this study (I-817). They also acknowledge patient families, faculty, staff and residents of dermatology department, particularly Aditi Jha, Prateek Sondhi, Tanvi Dev, Deepthi Talwar, Ashutsoh Vats, and Apoorva Challa for their support in conduct of this study.

Funding

Indian Council for Medical Research (ICMR, I-817).

Author information

Author notes

  1. Vamsi K. Yenamandra and Prakash Khute contributed equally and are to be considered as joint first-authors.

Authors and Affiliations

  1. Department of Dermatology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Vamsi K. Yenamandra, Prakash Khute, Deepika Yadav, Arunachalam Narayanan, Sindhuja Tekumalla, Vinod K. Sharma & Gomathy Sethuraman

  2. CSIR-Institute of Genomics & Integrative Biology, New Delhi, India

    Vamsi K. Yenamandra

  3. Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India

    Vamsi K. Yenamandra

  4. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 110029, India

    Sreenivas V

  5. Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India

    Sushil K. Kabra

Authors
  1. Vamsi K. Yenamandra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prakash Khute
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deepika Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arunachalam Narayanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sindhuja Tekumalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sreenivas V
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sushil K. Kabra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vinod K. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gomathy Sethuraman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

VKY, PK, SV, GS conceptualised and designed the study, supervised and coordinated the data collection; VKY and GS drafted the initial manuscript, critically revised and approved the final manuscript as submitted; DY, AN, ST, SKK, VKS contributed to data collection and analysis, critically revised and approved the final manuscript as submitted; SV carried the statistical analysis, critically revised and approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work. GS will act as guarantor for this manuscript.

Corresponding author

Correspondence to Gomathy Sethuraman.

Ethics declarations

Conflict of Interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yenamandra, V.K., Khute, P., Yadav, D. et al. Oral Propranolol Therapy for Infantile Hemangioma: Long-term Follow-up. Indian J Pediatr 90, 937–939 (2023). https://doi.org/10.1007/s12098-023-04586-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-023-04586-w

Keywords

Search

Navigation